- Home
- CREV vs NCNA Comparison
CREV vs NCNA Comparison
Compare CREV & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CREV
- NCNA
- Stock Information
- Founded
- CREV 2007
- NCNA 1997
- Country
- CREV Australia
- NCNA United Kingdom
- Employees
- CREV N/A
- NCNA N/A
- Industry
- CREV
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- CREV
- NCNA Health Care
- Exchange
- CREV Nasdaq
- NCNA Nasdaq
- Market Cap
- CREV 7.0M
- NCNA 7.6M
- IPO Year
- CREV N/A
- NCNA 2017
- Fundamental
- Price
- CREV $5.52
- NCNA $4.25
- Analyst Decision
- CREV
- NCNA
- Analyst Count
- CREV 0
- NCNA 0
- Target Price
- CREV N/A
- NCNA N/A
- AVG Volume (30 Days)
- CREV 1.4M
- NCNA 728.9K
- Earning Date
- CREV 05-14-2025
- NCNA 11-24-2025
- Dividend Yield
- CREV N/A
- NCNA N/A
- EPS Growth
- CREV N/A
- NCNA N/A
- EPS
- CREV N/A
- NCNA N/A
- Revenue
- CREV $47,677,475.00
- NCNA N/A
- Revenue This Year
- CREV $40.32
- NCNA N/A
- Revenue Next Year
- CREV N/A
- NCNA N/A
- P/E Ratio
- CREV N/A
- NCNA N/A
- Revenue Growth
- CREV 86.77
- NCNA N/A
- 52 Week Low
- CREV $2.00
- NCNA $2.78
- 52 Week High
- CREV $12.75
- NCNA $366.00
- Technical
- Relative Strength Index (RSI)
- CREV 67.65
- NCNA 45.60
- Support Level
- CREV $4.71
- NCNA $3.81
- Resistance Level
- CREV $5.62
- NCNA $4.40
- Average True Range (ATR)
- CREV 0.47
- NCNA 0.51
- MACD
- CREV 0.14
- NCNA -0.20
- Stochastic Oscillator
- CREV 94.23
- NCNA 17.15
About CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.